We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Overtesting for Diabetes Tends to Reap Negative “Rewards”

By LabMedica International staff writers
Posted on 23 Dec 2015
Researchers report a US national trend toward overtesting of glycated hemoglobin (HbA1c) levels in adult patients with Type 2 diabetes, leading to unnecessary cost, time, and other burdens for patients and providers, as well as potential patient health complications due to overtreatment with hypoglycemic drugs.

A new study led by Mayo Clinic (Rochester, MN, USA) researchers has shown that patients with Type 2 diabetes are often tested much more frequently than clinically indicated. More...
Type 2 diabetes monitoring and treatment protocols are not well defined by professional societies and regulatory bodies. While lower thresholds of testing frequencies are often discussed, the upper boundaries are rarely mentioned. Yet, most agree that checking 1–2 times/year should suffice for adult patients who are not using insulin, have stable glycemic control within the recommended targets, and have no history of severe hypoglycemia or hyperglycemia. Yet, in practice, there is a much higher prevalence of excessive testing.

Upon examining a national cohort of 31,545 non-pregnant adults with controlled non-insulin-treated Type 2 diabetes, the investigators said the study provides definitive evidence of such excess testing. The patient cohort examined was derived from the OptumLabs Data Warehouse (OLDW) using de-identified administrative, pharmacy, and laboratory data from 2001 to 2011. Approximately 55% achieved and maintained the recommended less than 7% HbA1c level and were tested 3–4 times/year; 6% were tested 5 or more times.

“Our findings are concerning, especially as we focus more on improving the value of care we deliver to our patients—not only ensuring maximal benefit, but also being mindful of waste, patient burden, and healthcare costs,” said study lead investigator Rozalina McCoy, MD, Mayo Clinic, “As providers, we must be ever vigilant.”

“Potential reasons for more frequent testing include clinical uncertainty; misunderstanding of the nature of the test—that is, not realizing that HbA1c represents a 3-month average of glycemic control; or a desire for diagnostic and management thoroughness,” said Dr. McCoy, “Other times, it may be the result of fragmentation of care (more than one unconnected provider); the need to fulfill regulatory demands, such as public reporting of performance metrics; or internal tracking of performance. “Because our culture often thinks that more is better” patients and providers may favor additional testing due to a desire for comprehensive care, she added.

The researchers also found that excessive testing increased the odds of overtreatment with one or more drugs, despite normal HbA1c levels, and that rates of overtesting were lower among patients receiving bundled testing (i.e., cholesterol, creatinine, and HbA1c tests in the same day).

“We hope that these findings will help inform decision-making,” said Dr. McCoy.

The study was published December 8, 2015, in the British Journal of Medicine.

Related Links:

Mayo Clinic
Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery
OptumLabs 



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.